Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled HMW-HA (Yabro) for Severe COVID-19
NCT04830020Phase 2Completed
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Feb 2021
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sodium hyaluronate in coronavirus disease 2019 (COVID-19), sponsored by Università Campus Bio-Medico di Roma. Started Feb 2021; status: completed.
02
Drugs
sodium hyaluronate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04830020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830020.